公开(公告)号：EP1373262B1

公开(公告)日：2010-05-12

申请号：EP02726168.4

申请日：2002-03-13

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： FUJIMOTO, Roger, Aki ,  MCQUIRE, Leslie, Wighton ,  MONOVICH, Lauren, G. ,  NANTERMET, Philippe ,  PARKER, David, Thomas ,  ROBINSON, Leslie, Ann ,  SKILES, Jerry, W. ,  TOMMASI, Ruben, Alberto

IPC分类号： C07D409/12

CPC分类号： C07D401/12 ,  C07D211/34 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12

摘要： Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsufonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.

公开(公告)号：EP1373262A2

公开(公告)日：2004-01-02

申请号：EP02726168.4

申请日：2002-03-13

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： FUJIMOTO, Roger, Aki ,  MCQUIRE, Leslie, Wighton ,  MONOVICH, Lauren, G. ,  NANTERMET, Philippe ,  PARKER, David, Thomas ,  ROBINSON, Leslie, Ann ,  SKILES, Jerry, W. ,  TOMMASI, Ruben, Alberto

IPC分类号： C07D409/12

CPC分类号： C07D401/12 ,  C07D211/34 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12

摘要： Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsufonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.